SLC5A2 and Decreased total neutrophil count: As the SGLT2 inhibitor empagliflozin has been used off label for neutropenia and neutrophil dysfunction in patients with GSD Ib since 2020 worldwide, patients in our cohort received empagliflozin treatment as well.